Cattle encephalon glycoside and ignotin(CEGI)injection is a compound preparation formed by a combination of muscle extract from hea lthy rabbits and brain gangliosides from cattle,and it is generally used as a neuropr...Cattle encephalon glycoside and ignotin(CEGI)injection is a compound preparation formed by a combination of muscle extract from hea lthy rabbits and brain gangliosides from cattle,and it is generally used as a neuroprotectant in the treatment of central and peripheral nerve injuries.However,there is still a need for high-level clinical evidence from large samples to support the use of CEGI.We therefore carried out a prospective,multicenter,randomized,double-blind,parallel-group,placebo-controlled study in which we recruited 319 patients with acute cerebral infarction from 16 centers in China from October 2013 to May 2016.The patients were randomized at a 3:1 ratio into CEGI(n=239;155 male,84 female;61.2±9.2 years old)and placebo(n=80;46 male,34 female;63.2±8.28 years old)groups.All patients were given standard care once daily for 14 days,including a 200 mg aspirin enteric-coated tablet and 20 mg atorvastatin calcium,both taken orally,and intravenous infusion of 250–500 mL 0.9%sodium chloride containing 40 mg sodium tanshinone IIA sulfonate.Based on conventional treatment,patients in the CEGI and placebo groups were given 12 mL CEGI or 12 mL sterile water,respectively,in an intravenous drip of 250 mL 0.9%sodium chloride(2 mL/min)once daily for 14 days.According to baseline National Institutes of Health Stroke Scale scores,patients in the two groups were divided into mild and moderate subgroups.Based on the modified Rankin Scale results,the rate of patients with good outcomes in the CEGI group was higher than that in the placebo group,and the rate of disability in the CEGI group was lower than that in the placebo group on day 90 after treatment.In the CEGI group,neurological deficits were decreased on days 14 and 90 after treatment,as measured by the National Institutes of Health Stroke Scale and the Barthel Index.Subgroup analysis revealed that CEGI led to more significant improvements in moderate stroke patients.No drug-related adverse events occurred in the CEGI or placebo groups.In conclusion,CEGI may be a safe and effective treatment for acute cerebral infarction patients,especially for moderate stroke patients.This study was approved by the Ethical Committee of Peking University Third Hospital,China(approval No.2013-068-2)on May 20,2013,and registered in the Chinese Clinical Trial Registry(registration No.ChiCTR1800017937).展开更多
Major ozonated autohemotherapy is classically used in treating ischemic disorder of the lower limbs In the present study, we performed major ozonated autohemotherapy treatment in patients with acute cerebral infarctio...Major ozonated autohemotherapy is classically used in treating ischemic disorder of the lower limbs In the present study, we performed major ozonated autohemotherapy treatment in patients with acute cerebral infarction, and assessed outcomes according to the U.S. National Institutes of Health Stroke Score, Modified Rankin Scale, and transcranial magnetic stimulation motor-evoked potential. Compared with the control group, the clinical total effective rate and the cortical potential rise rate of the upper limbs were significantly higher, the central motor conduction time of upper limb was significantly shorter, and the upper limb motor-evoked potential amplitude was significantly increased, in the ozone group. In the ozone group, the National Institutes of Health Stroke Score was positively correlated with the central motor conduction time and the motor-evoked potential amplitude of the upper limb. Central motor conduction time and motor-evoked potential amplitude of the upper limb may be effective indicators of motor-evoked potentials to assess upper limb motor function in cerebral infarct patients. Furthermore, major ozonated autohemotherapy may promote motor function recovery of the upper limb in patients with acute cerebral infarction.展开更多
Acute ST segment elevation myocardial infarction(STEMI) is characterized by complete thrombotic occlusion of a major coronary artery. Early recanalization of the infarct-related artery is most efficiently delivered by...Acute ST segment elevation myocardial infarction(STEMI) is characterized by complete thrombotic occlusion of a major coronary artery. Early recanalization of the infarct-related artery is most efficiently delivered by primary percutaneous coronary intervention(PPCI),however this does not always restore normal myocardial perfusion,mainly due to distal embolization of the thrombus and microvascular obstruction. Early evidence for manual thrombus aspiration during PPCI was promising and this was once considered an important aspect of the procedure,especially in patients with a high thrombus burden. However,a large body of evidence from recent major randomized controlled trials(notably TASTE and TOTAL) does not support the routine use of manual thrombus aspiration in patients with STEMI undergoing PPCI.展开更多
Objective: To summarize a decade of research on various aspects of Sowthistle-leaf Ixeris seedling for acute cerebral infarction. Methods: Thirty-six papers were collected from searches of CNKI, Wanfang, PubMed, and o...Objective: To summarize a decade of research on various aspects of Sowthistle-leaf Ixeris seedling for acute cerebral infarction. Methods: Thirty-six papers were collected from searches of CNKI, Wanfang, PubMed, and other databases and then they were summarized. Results: Researchers have carried out widespread and various pharmacological studies of Sowthistle-leaf Ixeris seedling, and have pursued different research directions on its etiology and pathogenesis, syndrome differentiation and treatment methods for acute cerebral infarction (ischemic stroke). With the development of Chinese medicine, its safety and non-toxic side effects have been recognized by the majority of scholars. The research results have contributed significantly to the treatment of acute cerebral infarction by Sowthistle-leaf Ixeris seedling. Conclusion: Sowthistle-leaf Ixeris seedling has extensive medicinal value and unique advantages in the treatment of acute cerebral infarction, especially in expanding brain vessels, increasing blood flow, reducing thrombosis, protecting brain cells, improving neurological impairment, and it has no toxic side effects.展开更多
目的 探讨扶阳急救汤加减治疗急性脑梗死患者的疗效及对患者中医证候评分、卒中量表评分和凝血功能的影响。方法 将2020年6月—2022年6月安徽中医药大学附属太和中医院收治的120例急性脑梗死患者随机等分为观察组和对照组。对照组给予...目的 探讨扶阳急救汤加减治疗急性脑梗死患者的疗效及对患者中医证候评分、卒中量表评分和凝血功能的影响。方法 将2020年6月—2022年6月安徽中医药大学附属太和中医院收治的120例急性脑梗死患者随机等分为观察组和对照组。对照组给予抗血小板聚集等治疗措施,观察组在此基础上联合扶阳急救汤加减治疗。两组均持续治疗2周。比较两组患者的临床疗效、中医证候评分、美国国立卫生研究院卒中量表(National Institute of Health stroke scale, NIHSS)评分、凝血功能及3个月后改良RANKIN量表(Modified Rankin Scale, mRS)评分。结果 治疗后,观察组总有效率较高(P<0.05)。治疗1周、2周后,两组中医证候主证、次证、总积分和NIHSS评分逐渐明显降低(P<0.05),且观察组显著低于对照组(P<0.05)。治疗2周后,对照组凝血酶原时间(Prothrombin time, PT)、活化的部分凝血活酶时间(Activated partial thromboplastin time, APTT)、纤维蛋白原(Fibrinogen, FIB)、凝血酶时间(Thrombin time, TT)水平较治疗前差异无统计学意义(P>0.05),观察组PT、TT水平较治疗前差异无统计学意义(P>0.05),APTT及FIB水平则明显降低(P<0.05),且显著低于对照组(P<0.05)。治疗后3个月,观察组mRS评分显著低于对照组(P<0.05)。结论 扶阳急救汤加减治疗可以更好地促进痰瘀阻络证型急性脑梗死患者神经功能及中医证候的恢复,提高患者近期疗效及长期生活质量,且并未影响凝血功能,有较好的安全性,值得临床应用。展开更多
文摘Cattle encephalon glycoside and ignotin(CEGI)injection is a compound preparation formed by a combination of muscle extract from hea lthy rabbits and brain gangliosides from cattle,and it is generally used as a neuroprotectant in the treatment of central and peripheral nerve injuries.However,there is still a need for high-level clinical evidence from large samples to support the use of CEGI.We therefore carried out a prospective,multicenter,randomized,double-blind,parallel-group,placebo-controlled study in which we recruited 319 patients with acute cerebral infarction from 16 centers in China from October 2013 to May 2016.The patients were randomized at a 3:1 ratio into CEGI(n=239;155 male,84 female;61.2±9.2 years old)and placebo(n=80;46 male,34 female;63.2±8.28 years old)groups.All patients were given standard care once daily for 14 days,including a 200 mg aspirin enteric-coated tablet and 20 mg atorvastatin calcium,both taken orally,and intravenous infusion of 250–500 mL 0.9%sodium chloride containing 40 mg sodium tanshinone IIA sulfonate.Based on conventional treatment,patients in the CEGI and placebo groups were given 12 mL CEGI or 12 mL sterile water,respectively,in an intravenous drip of 250 mL 0.9%sodium chloride(2 mL/min)once daily for 14 days.According to baseline National Institutes of Health Stroke Scale scores,patients in the two groups were divided into mild and moderate subgroups.Based on the modified Rankin Scale results,the rate of patients with good outcomes in the CEGI group was higher than that in the placebo group,and the rate of disability in the CEGI group was lower than that in the placebo group on day 90 after treatment.In the CEGI group,neurological deficits were decreased on days 14 and 90 after treatment,as measured by the National Institutes of Health Stroke Scale and the Barthel Index.Subgroup analysis revealed that CEGI led to more significant improvements in moderate stroke patients.No drug-related adverse events occurred in the CEGI or placebo groups.In conclusion,CEGI may be a safe and effective treatment for acute cerebral infarction patients,especially for moderate stroke patients.This study was approved by the Ethical Committee of Peking University Third Hospital,China(approval No.2013-068-2)on May 20,2013,and registered in the Chinese Clinical Trial Registry(registration No.ChiCTR1800017937).
基金supported by the Guangdong Province Medical Science Research Fund, No. B200258
文摘Major ozonated autohemotherapy is classically used in treating ischemic disorder of the lower limbs In the present study, we performed major ozonated autohemotherapy treatment in patients with acute cerebral infarction, and assessed outcomes according to the U.S. National Institutes of Health Stroke Score, Modified Rankin Scale, and transcranial magnetic stimulation motor-evoked potential. Compared with the control group, the clinical total effective rate and the cortical potential rise rate of the upper limbs were significantly higher, the central motor conduction time of upper limb was significantly shorter, and the upper limb motor-evoked potential amplitude was significantly increased, in the ozone group. In the ozone group, the National Institutes of Health Stroke Score was positively correlated with the central motor conduction time and the motor-evoked potential amplitude of the upper limb. Central motor conduction time and motor-evoked potential amplitude of the upper limb may be effective indicators of motor-evoked potentials to assess upper limb motor function in cerebral infarct patients. Furthermore, major ozonated autohemotherapy may promote motor function recovery of the upper limb in patients with acute cerebral infarction.
文摘Acute ST segment elevation myocardial infarction(STEMI) is characterized by complete thrombotic occlusion of a major coronary artery. Early recanalization of the infarct-related artery is most efficiently delivered by primary percutaneous coronary intervention(PPCI),however this does not always restore normal myocardial perfusion,mainly due to distal embolization of the thrombus and microvascular obstruction. Early evidence for manual thrombus aspiration during PPCI was promising and this was once considered an important aspect of the procedure,especially in patients with a high thrombus burden. However,a large body of evidence from recent major randomized controlled trials(notably TASTE and TOTAL) does not support the routine use of manual thrombus aspiration in patients with STEMI undergoing PPCI.
基金the National Natural Science Foundation of the People's Republic of China (Grant Nos. 81704051, 81173233)the Scientific Research Foundation for Returned Oversea Chinese Scholars, State Education Ministry (2014)+1 种基金the TCM Standardization Project of the State Administration of Traditional Chinese Medicine (No. ZYYS-2013PJ07)the Talent Cultivation Project of Dongfang Hospital, Beijing University of Chinese Medicine (2015–2017).
文摘Objective: To summarize a decade of research on various aspects of Sowthistle-leaf Ixeris seedling for acute cerebral infarction. Methods: Thirty-six papers were collected from searches of CNKI, Wanfang, PubMed, and other databases and then they were summarized. Results: Researchers have carried out widespread and various pharmacological studies of Sowthistle-leaf Ixeris seedling, and have pursued different research directions on its etiology and pathogenesis, syndrome differentiation and treatment methods for acute cerebral infarction (ischemic stroke). With the development of Chinese medicine, its safety and non-toxic side effects have been recognized by the majority of scholars. The research results have contributed significantly to the treatment of acute cerebral infarction by Sowthistle-leaf Ixeris seedling. Conclusion: Sowthistle-leaf Ixeris seedling has extensive medicinal value and unique advantages in the treatment of acute cerebral infarction, especially in expanding brain vessels, increasing blood flow, reducing thrombosis, protecting brain cells, improving neurological impairment, and it has no toxic side effects.
文摘目的 探究标准剂量rt-PA静脉溶栓联合动脉取栓治疗急性脑梗死的效果。方法 随机选取海阳市人民医院于2021年7月—2023年7月收治的80例急性脑梗死患者为研究对象,通过随机数表法分成溶栓组与桥接组,各40例。溶栓组运用标准量静脉溶栓治疗,桥接组在经过30 min静脉溶栓治疗之后,对治疗效果不理想的患者,进行机械取栓。比较两组的国立卫生研究院卒中量表(National Institute of Health Stroke Scale,NIHSS)评分以及不良反应发生情况。结果 治疗后24 h、7 d、30 d,桥接组的NIHSS评分均低于溶栓组,差异有统计学意义(P均<0.05)。桥接组的不良反应总发生率为7.50%,溶栓组为2.50%,两组对比,差异无统计学意义(χ^(2)=0.263,P>0.05)。结论 标准剂量rt-PA静脉溶栓联合动脉取栓治疗有效地促进了患者神经功能的恢复,不良反应与溶栓治疗相当,对急性脑梗死的治疗提供了有力的支持。
文摘目的 探讨扶阳急救汤加减治疗急性脑梗死患者的疗效及对患者中医证候评分、卒中量表评分和凝血功能的影响。方法 将2020年6月—2022年6月安徽中医药大学附属太和中医院收治的120例急性脑梗死患者随机等分为观察组和对照组。对照组给予抗血小板聚集等治疗措施,观察组在此基础上联合扶阳急救汤加减治疗。两组均持续治疗2周。比较两组患者的临床疗效、中医证候评分、美国国立卫生研究院卒中量表(National Institute of Health stroke scale, NIHSS)评分、凝血功能及3个月后改良RANKIN量表(Modified Rankin Scale, mRS)评分。结果 治疗后,观察组总有效率较高(P<0.05)。治疗1周、2周后,两组中医证候主证、次证、总积分和NIHSS评分逐渐明显降低(P<0.05),且观察组显著低于对照组(P<0.05)。治疗2周后,对照组凝血酶原时间(Prothrombin time, PT)、活化的部分凝血活酶时间(Activated partial thromboplastin time, APTT)、纤维蛋白原(Fibrinogen, FIB)、凝血酶时间(Thrombin time, TT)水平较治疗前差异无统计学意义(P>0.05),观察组PT、TT水平较治疗前差异无统计学意义(P>0.05),APTT及FIB水平则明显降低(P<0.05),且显著低于对照组(P<0.05)。治疗后3个月,观察组mRS评分显著低于对照组(P<0.05)。结论 扶阳急救汤加减治疗可以更好地促进痰瘀阻络证型急性脑梗死患者神经功能及中医证候的恢复,提高患者近期疗效及长期生活质量,且并未影响凝血功能,有较好的安全性,值得临床应用。
